NeoPharm Return On Equity vs. Cash And Equivalents
| 092730 Stock | KRW 12,000 90.00 0.74% |
For NeoPharm profitability analysis, we use financial ratios and fundamental drivers that measure the ability of NeoPharm to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well NeoPharm LTD utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between NeoPharm's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of NeoPharm LTD over time as well as its relative position and ranking within its peers.
NeoPharm |
NeoPharm LTD Cash And Equivalents vs. Return On Equity Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining NeoPharm's current stock value. Our valuation model uses many indicators to compare NeoPharm value to that of its competitors to determine the firm's financial worth. NeoPharm LTD is number one stock in return on equity category among its peers. It also is number one stock in cash and equivalents category among its peers creating about 510,074,566 of Cash And Equivalents per Return On Equity. Comparative valuation analysis is a catch-all model that can be used if you cannot value NeoPharm by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for NeoPharm's Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.NeoPharm Cash And Equivalents vs. Return On Equity
Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.
NeoPharm |
| = | 13.82 |
For most industries, Return on Equity between 10% and 30% are considered desirable to provide dividends to owners and have funds for the future growth of the company. Investors should be very careful using ROE as the only efficiency indicator because ROE can be high if a company is heavily leveraged.
Cash or Cash Equivalents are the most liquid of all assets found on the company's balance sheet. It is used in calculating many of the firm's liquidity ratios and is a good indicator of the overall financial health of a company. Companies with a lot of cash are usually attractive takeover targets. Cash Equivalents are balance sheet items that are typically reported using currency printed on notes.
NeoPharm |
| = | 7.05 B |
Cash equivalents represent current assets that are easily convertible to cash such as short term bonds, savings account, money market funds, or certificate of deposits (CDs). One of the important consideration companies make when classifying assets as cash equivalent is that investments they report on their balance sheets under current assets should have almost no risk of change in value over the next few months (usually three months).
NeoPharm Cash And Equivalents Comparison
NeoPharm is currently under evaluation in cash and equivalents category among its peers.
NeoPharm Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in NeoPharm, profitability is also one of the essential criteria for including it into their portfolios because, without profit, NeoPharm will eventually generate negative long term returns. The profitability progress is the general direction of NeoPharm's change in net profit over the period of time. It can combine multiple indicators of NeoPharm, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
,Ltd. manufactures and sells skin care products in Korea and internationally. ,Ltd. was founded in 2000 and is headquartered in Daejeon, South Korea. Neopharm is traded on Korean Securities Dealers Automated Quotations in South Korea.
NeoPharm Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on NeoPharm. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of NeoPharm position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the NeoPharm's important profitability drivers and their relationship over time.
Learn to be your own money manager
Our tools can tell you how much better you can do entering a position in NeoPharm without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run USA ETFs Now
USA ETFsFind actively traded Exchange Traded Funds (ETF) in USA |
| All Next | Launch Module |
Use Investing Themes to Complement your NeoPharm position
In addition to having NeoPharm in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Utilities - Regulated Electric Thematic Idea Now
Utilities - Regulated Electric
Fama and French investing themes focus on testing asset pricing under different economic assumptions. The Utilities - Regulated Electric theme has 7 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Utilities - Regulated Electric Theme or any other thematic opportunities.
| View All Next | Launch |
Other Information on Investing in NeoPharm Stock
To fully project NeoPharm's future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of NeoPharm LTD at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include NeoPharm's income statement, its balance sheet, and the statement of cash flows.